Oddo BHF - Virbac SA (VIRP) Virbac : Q3 2020 sales: organic improvement– Guidance lifted – target price: € 225

Report

Oddo BHF

Christophe-Raphaël Ganet

Virbac : Q3 2020 sales: organic improvement– Guidance lifted – target price: € 225

>Q3: more marked forex impact, but improvement in organic performance - Reported Q3 sales amounted to € 235.6m, up 0.9% (up 6.8% in absolute terms and 11.1% excl. Sentinel). The sharp depreciation of certain currencies (BRL, MXP, ZAR, INR) weighed significantly on Q3. Excluding the impact of the disposal of Sentinel in the US, all regions were nevertheless up compared with the corresponding period of 2019.At end-September, sales amounted to € 714m, and € 67...

15/10/2020 4 EN

Underlying

Virbac SA

Virbac is an independent veterinary pharmaceutical laboratory. Co. develops and provides veterinarians and farmers with medicines and vaccines that improve the health of food producing animals. Co. markets a range of products designed for pets and livestock. It offers seven types of products for companion animals (Parasiticides, Immunology, Antibiotics/dermatology, Specialties, Equine, Specialized pet food and Other products), and four types of products for food producing animals (Bovine parasiticides, Bovine products (excluding parasiticides), Pig/poultry antibiotics and Other products). Co. markets its products in the ethical (veterinarian) and OTC markets.

See profile

FR0000031577 Euronext Paris France

Provider

Oddo BHF

Oddo Securities provides securities brokerage and research services. The company offers equity, economic, and derivatives research and credit analysis services. It focuses on insurance, automotive, building materials, pharmaceuticals, telecommunications, information technology, and agri-food industries.

See profile

Analysts

Christophe-Raphaël Ganet

Other Reports on these Companies

GlobeNewsWire

Virbac : Public release of Virbac Annual Report at 31 December 2023 (ESEF format)

Virbac : Public release of Virbac Annual Report at 31 December 2023 (ESEF format) Public release of Virbac Annual Report at 31 December 2023 (ESEF format). The Group released and filed its 2023 Annual Report with the French “Autorité des marchés financiers”. The document is also available on the corporate website, at corporate.virbac.com, under “Investors”, “Financial Reports” at the ESEF format and pdf format. Attachment

13h / 49m 13h / 49m 1 EN

GlobeNewsWire

Virbac : Communiqué de mise à disposition du Rapport Annuel au format ESEF au 31 décembre 2023

Virbac : Communiqué de mise à disposition du Rapport Annuel au format ESEF au 31 décembre 2023 Communiqué de mise à disposition du Rapport Annuel au format ESEF au 31 décembre 2023. Le Groupe annonce avoir mis à la disposition du public et déposé auprès de l’Autorité des marchés financiers son Rapport Annuel au format ESEF au 31 décembre 2023. Le rapport annuel peut également être consulté sur le site internet du Groupe, à l’adresse corporate.virbac.com, dans la rubrique « Investisseurs», puis « Rapports financiers », au format XBRL et au format pdf. Pièce jointe ...

13h / 49m 13h / 49m 1 EN

SmartInsider

Virbac: 1 director

A director at Virbac sold 3,008 shares at 365.039EUR and the significance rating of the trade was 96/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last two years clearly showing Close periods where trading activity is restricted under listing rules. The names of board members...

Free Trial

April 19, 2024 April 19, 2024 1 EN

KONE : Un T1 qui rassure, la guidance 2024 est précisée

>Un T1 un peu meilleur qu’attendu - KONE a publié hier matin des résultats T1 un peu meilleurs qu’attendu. Les commandes progressent de 1.6% à changes constants (css à 0.9%), grâce notamment au segment modernisation qui progresse de plus de 10%. Le chiffre d’affaires a augmenté de 2.7% à changes constants au T1 (consensus : +2.3%), avec une Chine en recul de 4.9%. En termes d’activité, les nouveaux équipements reculent (-4.2% à changes constants), les services (+9%) e...

1m 1m 1 FR

Delphine Brault ... (+2)

Delphine Brault
Quentin Borie

Assa Abloy : Start of year in decline (-4% by volume), set to mark low point

>Q1 2024: volumes at -4% for top line, but margins still very solid - The group’s Q1 2024 results, reported yesterday morning, were in line with expectations at the operating level. Revenues came in 2% lower in organic terms, with -4% of volume effect (4th straight quarter of negative volumes, after -2% in Q4) and +2% of price effect.Adjusted EBIT came to SEK 5.4bn, up 4.6%, while the margin narrowed 60bp to 15.4%, just ahead of expectations (15.2%). The acquisit...

1m 1m 1 EN

Anthony Dick ... (+2)

Anthony Dick
Michael Foundoukidis

Volkswagen (pref) : China ambitions again reiterated, but still require both faith and patience

>Near-term challenges remain, improvement thereafter unlikely to be pencilled in - VW held a CMD in China yesterday (PR link), where the OEM reaffirmed and detailed its "China for China" strategy in the country and its ambitions. In a nutshell, our view would be that there was not much news from VW, with the China story still requiring both a lot of faith and patience. As VW management once again seems to be emphasizing, the next two years (at least) will remain chall...

1m 1m 1 EN

Sign-up for free to access full reports immediately

Email Address*

Choose Password* ( 6 or more characters )

Due to regulatory restrictions regarding the distribution of financial research, this report is restricted to a specific region or investor type. Get access to exclusive reports by answering the questions below.

Select your country*

Get financial insights straight to your inbox

By clicking "register" you accept the Terms and Conditions & Privacy Policy

Already on ResearchPool?

Almost there...

Are you a professional investor?

Select your country

REGISTER

Create a free ResearchPool account to access full reports, get a personalised dashboard and follow providers or companies

In order to access this report please create an account.

LOGIN